Skip to main content Skip to footer

Summit Therapeutics plc, the Oxford based drug discovery and development company advancing therapies for rare and infectious diseases, announced today that it has raised £15 million.

The Placing, which was oversubscribed, was conducted by means of an accelerated bookbuild with existing and new investors.

The funds will be used primarily to accelerate preparatory activities for a placebo controlled clinical trial of ezutromid, and for a potential regulatory filing of ezutromid in Duchenne muscular dystrophy (“DMD”) based on the 48-week results from the ongoing Phase 2 clinical trial called PhaseOut DMD

Singer Capital Markets acted as joint broker in relation to the Placing.

Ticker: SUMM

For further information please contact